Stock listing

Idorsia Ltd.

Selected listing: IDIA · SIX · CHF · CH

Idorsia Ltd. (SIX Swiss: IDIA), Health Technology. Latest release Aug 11, 2026: Idorsia acknowledges the DEA proposal to reclassify dual orexin receptor…

IDIA:SIXCHFCHUpdated October 2, 2026

Ticker: SIX Swiss: IDIA
Asset type: Stock
Sector: Health Technology
Industry: Pharmaceuticals: Major
Exchange: SIX Swiss
Currency: CHF

About Idorsia Ltd.

Idorsia Ltd. is a public company based in Switzerland, trading under the ticker IDIA. Idorsia focuses on developing innovative therapies to address unmet medical needs.

Latest news from Idorsia Ltd.

Idorsia acknowledges the DEA proposal to reclassify dual orexin receptor antagonists to the lowest schedule – Schedule V

August 11, 2026

QUVIVIQ sales increased 62% year-on-year as Idorsia advances key drivers of future growth

July 30, 2026

Idorsia advances global rollout of QUVIVIQ with Jamjoom Pharma partnership in Saudi Arabia and the Levant

July 27, 2026

Invitation to Idorsia's HY 2026 Financial Reporting webcast and conference call

July 23, 2026

Idorsia appoints Roland Wandeler as Chief Executive Officer

July 1, 2026

All Idorsia Ltd. news →

Events

Replays

Idorsia Pharmaceuticals Ltd (IDRSF) Q2 2026 Earnings Call
Thu, Jul 30, 2026 · 09:00 AM ET
Watch
Idorsia Pharmaceuticals Ltd (IDRSF) Q4 2025 Earnings Call
Thu, Feb 26, 2026 · 08:00 AM ET
Watch
Idorsia Pharmaceuticals Ltd (IDRSF) Q2 2025 Earnings Call
Wed, Jul 30, 2025 · 08:00 AM ET
Watch

Research Idorsia Ltd.

Idorsia Ltd. company profile

View the public company page for Idorsia Ltd. on 6ix.

Idorsia Ltd. news

Read company news and market updates connected to Idorsia Ltd..

Idorsia Ltd. investor events

Find investor webinars, events, and replay context for Idorsia Ltd..